Test Your Skills: Medullary Thyroid Cancer

CE / CME

Test Your Skills: Understanding the Current Biomarker Landscape for Patients With Medullary Thyroid Cancer

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurses: 0.25 Nursing contact hour

Pharmacists: 0.25 contact hour (0.025 CEUs)

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Released: September 17, 2024

Expiration: September 16, 2025

Joseph H. Friedman
Joseph H. Friedman, MD
Saad A Khan
Saad A Khan, MD
Diane K. Newman
Diane K. Newman, DNP, ANP-BC, FAAN
Steven Christopher Smith
Steven Christopher Smith, MD, PhD
Laura J. Tafe
Laura J. Tafe, MD

Activity

Progress
1 2
Course Completed

  1. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: thyroid carcinoma. v 4.2024. nccn.org. Accessed September 12, 2024.
  2. Thomas CM, Asa SL, Ezzat S, et al. Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines. Curr Oncol. 2019;26:338-344.
  3. Belli C, Penault-Llorca F, Ladanyi M, et al. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann Oncol. 2021;32:337-350.
  4. Santoro M, Carlomagno F. Central role of RET in thyroid cancer. Cold Spring Harb Perspect Biol. 2013;5:a009233.
  5. Selpercatinib [prescribing information]. Indianapolis, IN: Lilly USA; 2024.
  6. Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383:825-835.
  7. Morgenstern DA, Casanova M, van Tilburg CM, et al. Safety and efficacy of selpercatinib in pediatric patients with RET-altered solid tumors: updated results from LIBRETTO-121 Presented at: 2024 ASCO Annual Meeting; May 31 - June 4, 2024. Abstract 10022.
  8. Ernst D. Gavreto indication for RET-mutant medullary thyroid cancer withdrawn. www.empr.com/home/news/gavreto-indication-for-ret-mutant-medullary-thyroid-cancer-withdrawn/#:~:text=Genentech%2C%20in%20partnership%20with%20Blueprint%20Medicines%2C%20has%20voluntarily,medullary%20thyroid%20cancer%20%28MTC%29%20who%20require%20systemic%20therapy. Accessed September 12, 2024.
  9. Hadoux J, Elisei R, Brose MS, et al. Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med. 2023;389:1851-1861.